Sergei I. Provatorov

Sergei I. Provatorov

Auto-generated profile, based on publicly available information

Sergei I. Provatorov

Chazov National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Atherosclerosis
Verified
Journal Article
Closed access
APAlexandra Potekhina
Alexandra Potekhina
EPEkaterina Pylaeva
Ekaterina Pylaeva
SPSergey Provatorov
Sergey Provatorov
NRNatalya Ruleva
Natalya Ruleva
VMValery Masenko
Valery Masenko
TATatiana Arefieva
Tatiana Arefieva

24 February 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
SBSergey Boytsov
Sergey Boytsov
SPS I Provatorov
S I Provatorov
Dispensary observation of patients with coronary artery disease can significantly reduce the likelihood of cardiovascular complications onset. Active outpatient monitoring allows to correct the main risk factors for cardiovascular complications, to estimate the risk of unfavorable cardiovascular events onset and to identificate patients who will get benefit of coronary revascularization. The introduction of a comprehensive assessment of cardiovascular risk and the development of remote monitoring technologies will improve the long-term results of outpatient follow-up of patients with coronary artery disease at high cardiovascular risk.

15 September 2016 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
OAOlga Afanasieva
Olga Afanasieva
EPE A Pylaeva
E A Pylaeva
EKElena Klesareva
Elena Klesareva
APA V Potekhina
A V Potekhina
SPS I Provatorov
S I Provatorov
SPSergei N. Pokrovsky
Sergei N. Pokrovsky
Aim. To study the role of lipoprotein(a) [Lp(a)] as a potential autoantigen causing the activation of immunocompetent cells in atherosclerosis. Subjects and methods. A total of 104 men with stable coronary artery (CA) disease and different degrees of progressive coronary atherosclerosis were examined. Clinical blood analysis was carried out and lymphocyte subpopulations (CD4+, Th1, Th17, and Treg) were determined using immunofluorescence and flow cytometry. In addition, the indicators of blood lipid composition, Lp(a), autoantibody (autoAb) titer to Lp(a), and low-density lipoproteins (LDL), and the lymphocyte activation marker sCD25 were also measured. Results. The Lp(a) level was shown to predict the severity of CA lesions (β=0.28, p

30 October 2001 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Open access
PDF file
TATatiana Arefieva
Tatiana Arefieva
SPSergey I Provatorov
Sergey I Provatorov
ASAnatoly N Samko
Anatoly N Samko
TKTatiana L Krasnikova
Tatiana L Krasnikova
TRTherese J Resink
Therese J Resink
ECEugeniy I Chazov
Eugeniy I Chazov
SUMMARY: 1. In the present study, we sought to determine whether patients with restenosis after coronary stenting possess increased monocyte reactivity, as manifested by a higher level of adhesion molecule expression and an enhanced propensity to form monocyte–platelet aggregates after activation in vitro.2. Anti‐coagulated peripheral venous blood from 24 patients, 10 with and 14 without angiographically verified restenosis, was obtained. Leucocyte antigen expression and the number of leucocyte–platelet complexes were measured by flow cytometry after activation in whole blood.3. Surface integrin Mac‐1 (CD11b/CD18) and VLA‐4 (CD49d/ CD29) expression on monocytes and the relative number of monocyte–platelet complexes after in vitro activation were significantly elevated in patients with restenosis compared with patients without restenosis (fluorescence intensities of 1425 ± 76 vs 1195 ± 71, 87 ± 7 vs 65 ± 6 and 47 ± 4 vs 29 ± 3% for for Mac‐1, VLA‐4 and monocyte–platelet complexes, respectively; P < 0.05 for each parameter).4. The results suggest that restenosis is associated with increased monocyte VLA‐4 and Mac‐1 integrin expression and monocyte–platelet complex formation, which can be revealed after activation in vitro.

8 August 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
STS. N. Tereshchenko
S. N. Tereshchenko
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
TUT. M. Uskach
T. M. Uskach
AGAlbert Galyavich
Albert Galyavich
SPS. I. Provatorov
S. I. Provatorov
AYA. N. Yakovlev
A. N. Yakovlev
The article presents an overview of the largest randomized and observational studies on the efficacy and safety of primary percutaneous coronary intervention (PCI) and pharmacoinvasive strategy for ST-elevation myocardial infarction (STEMI).The management of STEMI patients is one of the most discussed and pressing issues in modern cardiology, since timely myocardial revascularization significantly affects both patient mortality and long-term prognosis. It has been established that the key factor in choosing reperfusion therapy for STEMI should be the time from the onset of symptoms. Due to the fact that it is not possible to ensure the time before opening the infarct-related artery up to 120 minutes in all patients referred for primary PCI in real-world practice, prehospital thrombolysis can significantly improve their prognosis. Pharmacoinvasive approach with prehospital bolus administration of thrombolytic agents should currently be considered as a priority strategy in STEMI if primary PCI within 120 min after diagnosis is not possible. A pharmacoinvasive approach with prehospital bolus administration of thrombolytic agents should be considered as an alternative to primary PCI in the first 3 hours from the STEMI onset in cases where primary PCI cannot be performed within 1 hour after diagnosis.

22 June 2023 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAleksandra M. Shchinova
Aleksandra M. Shchinova
APAlexandra Potekhina
Alexandra Potekhina
YDYuliya A. Dolgusheva
Yuliya A. Dolgusheva
YEYuliya E. Efremova
Yuliya E. Efremova
AOAnna K. Osokina
Anna K. Osokina
ПВПотехина Александра Викторовна
Потехина Александра Викторовна
Background: The extent of myocardial damage largely determines both in-hospital and long-term mortality in patients with acute coronary syndrome. According to the literature, the in-hospital and long-term mortality rates in patients with unstable angina (UA) are lower than those in the patients with myocardial infarction (MI). Aim: To evaluate the in-hospital and long-term mortality rates and their predictors in patients undergoing in-patient treatment for acute coronary syndrome (MI and UA) in the regional cardiovascular center with the service territory of 1 million persons. Materials and methods: This retrospective registry study enrolled 1130 patients (715 [63.3%] men, 415 [36.7%] women) who were treated for UA and MI in the regional cardiovascular center in 2019. Based on the discharge diagnosis, the patients were divided into two groups: patients with MI (n = 766) and those with an UA episode (n = 364). The in-hospital and delayed mortality rates, as well as their predictors, were analyzed in both groups. The mean duration of the follow-up was 17.8 3.6 months. Results: The in-hospital mortality in patients with confirmed MI was 11.1% (85 patients) versus 0.27% (1 patient) in the UA patients (p 0.001). The independent predictors of in-hospital mortality in MI patients were a decreased left ventricular ejection fraction (LV EF) (odds ratio (OR) 0.9021, 95% confidence interval (CI) 0.82090.9914, p = 0.0324), chronic kidney disease C3a and above (OR 9.3205, 95% CI 2.670632.5283, p = 0.0005), and the extension of coronary involvement at coronary angiography (OR 1.3526, 95% CI 1.06670.0127, p = 0.0127). The long-term mortality in MI patients was 10.4% (72 patients) with no significant difference from that in UA patients (9.9%, 36 patients, p = 0.76). The independent predictors of long-term mortality after MI were older age (OR 1.12, 95% CI 1.011.22, p = 0.0052), chronic kidney disease C3a and above (OR 2.3375, 95% CI 1.13924.7963, p = 0.0206), decreased EF (OR 0.8895, 95% CI 0.730.99, p = 0.0364), atrial fibrillation on admission (OR 3.1462, 95% CI 1.35107.3268, p = 0.0079), and diabetes mellitus (OR 2.3163, 95% CI 1.25524.2744, p = 0.0072). In the UA patients, the predictors of the long-term mortality were a decrease in LV EF (OR 0.9139, 95% CI 0.86830.9619, p = 0.0006) and in blood hemoglobin level (OR 0.9729, 95% CI 0.95440.9917, p = 0.0050). Conclusion: The in-hospital mortality in UA patients is lower than that in MI patients, with comparable long-term mortality. This indicates the need of active follow-up of the patients with past UA, irrespective of the endovascular assessment and intervention.